Medical Management
Applied
Type
ModificationConfidence
85%
Created
Mar 27, 2026
Evidence
3 sources
Rationale
The section was updated to incorporate the latest 2025 and 2026 guidelines and research. The 2025 ACC statement on PAD and diabetes was integrated to emphasize the need for intensive management in this high-risk population. The 2026 Saudi Heart Association guidelines were used to reinforce lifestyle and lipid management from an international perspective. A new point on risk stratification was added to include the SMART2-HF model for heart failure prediction in ASCVD patients, reflecting the growing importance of multi-morbidity management in vascular surgery. All abbreviations were expanded on first use as per instructions.
Evidence
Content Changes
removedadded
* **Lifestyle modification:** Smoking cessation reduces abdominal aortic aneurysm (AAA) expansion and peripheral arterial disease (PAD) progression [@golledge2017]. Exercise therapy improves walking distance in PAD. Comprehensive risk factor modification, including diet and physical activity, remains the cornerstone of cardiovascular prevention [@national2026]. * **Antiplatelet therapy:** Aspirin or clopidogrel for secondary prevention in symptomatic atherosclerotic disease [@lancet1996]. * **Anticoagulation:** Low-dose rivaroxaban plus aspirin benefits select PAD patients; see [[Peripheral Artery Disease|Ch. 10]] for COMPASS/VOYAGER-PAD evidence and patient selection criteria. * **Lipid lowering:** High-intensity statins reduce events and slow aneurysm growth.growth PCSK9[@national2026]. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide additional risk reduction in statin-intolerant or high-risk patients [@sabatine2017]. * **Blood pressure and glycemic control:** ACEAngiotensin-converting enzyme (ACE) inhibitors and tight glycemic control improve vascular outcomes [@aha2016]. In patients with diabetes and PAD, management requires intensive risk factor control and the use of evidence-based glucose-lowering therapies to reduce the risk of major adverse limb and cardiovascular events [@acc2025-d]. * **Risk stratification:** In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model can be utilized to predict the risk of incident heart failure, facilitating early intervention and personalized management [@reitsma2026-b].